UNSPSC 51432504: Perindoprilat

This classification denotes an ace inhibitor with the molecular formula C17H28N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2UV6ZNQ92K, chemically known as 1h-indole-2-carboxylic acid, octahydro-1-(2-((1-carboxybutyl)amino)-1-oxopropyl)-, (2s-(1(r*(r*)),2-alpha,3a-beta,7a-beta))- but generally known as perindoprilat, which bears US NIH Compound Identifier 72022. European Medicines Agency schedules Perindoprilat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09731MIG.

UNSPSC 51432504 Perindoprilat, a Commodity code, represents active pharmaceutical procurement by state and local government entities for emergency medical services and pharmacy benefit programs. State and local buyers under this code acquire specific medications—including perindoprilat and related advanced life support drugs—for use by fire-rescue departments, health benefit programs, and multi-jurisdictional cooperative purchasing alliances. The work spans direct procurement of individual medication line items with strict expiration and quality warranties, to broader multi-state cooperative pharmaceutical aggregation serving diverse health systems and government employee populations. Issuing bodies include municipal fire departments (via city purchasing offices), state health and human services commissions, and regional cooperative purchasing organizations that aggregate demand across state and local members. The Tampa Fire Rescue procurement and the Texas HHS pharmacy initiative represent the range of end-users—from tactical emergency response to large-scale benefit program design.

Activity under the code spans Florida, Texas, Minnesota, and Oregon, with recent solicitations reflecting both spot-purchase and longer-term alliance models. The City of Tampa's Purchasing Department issued IFB 26P00188 on April 24, 2026, for Advanced Life Support Medications (Labetalol, Epinephrine, Adenosine, Diltiazem) with a due date of April 8, 2026, and an estimated contract value of $40,000, applying a 5 percent SLBE bid discount. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Direct-to-Manufacturer Prescriptions program within its Therapeutic Pharmacy Initiative. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 on January 20, 2026, due March 26, 2026, for Generic Multi Source Pharmaceuticals and OTC Products distributed through authorized wholesalers to participating state and local government facilities in Minnesota and Oregon; the contract term runs two years with optional extensions, and vendors must meet cGMP and DSCSA compliance requirements with comprehensive insurance coverage including $5,000,000 general liability per occurrence.